Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era

doi:10.1007/s00432-022-04214-8

Review

. 2023 May;149(5):2071-2079.

doi: 10.1007/s00432-022-04214-8. Epub 2022 Jul 25.

Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era

Shaoli Wang^#¹, Siying Chen^#¹, Qionglei Zhong¹, Yan Liu²

Affiliations

¹ Otolaryngological Department, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Xiuhua Road, Haikou, Hainan, People's Republic of China.
² Otolaryngological Department, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road Xigang, Dalian, Liaoning, People's Republic of China. dyyyliuyan@163.com.

^# Contributed equally.

PMID: 35876949
DOI: 10.1007/s00432-022-04214-8

Review

Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era

Shaoli Wang et al. J Cancer Res Clin Oncol. 2023 May.

. 2023 May;149(5):2071-2079.

doi: 10.1007/s00432-022-04214-8. Epub 2022 Jul 25.

Authors

Shaoli Wang^#¹, Siying Chen^#¹, Qionglei Zhong¹, Yan Liu²

Affiliations

¹ Otolaryngological Department, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Xiuhua Road, Haikou, Hainan, People's Republic of China.
² Otolaryngological Department, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road Xigang, Dalian, Liaoning, People's Republic of China. dyyyliuyan@163.com.

^# Contributed equally.

PMID: 35876949
DOI: 10.1007/s00432-022-04214-8

Abstract

Purpose: Nasopharyngeal carcinoma (NPC) is ranked the top otorhinolaryngology malignant tumors in the world. However, the general prognosis of recurrent and metastatic (R/M) nasopharyngeal carcinomas (NPCs) remains poor, and current surgery and chemoradiotherapy do not generate satisfactory outcomes.

Methods: As a new therapeutic choice, immunotherapy, especially with regard to the development of checkpoint inhibitors including PD-1 and CTLA-4 inhibitors have made considerable progress in recent years. As Epstein-Barr virus (EBV) infection is associated with increased risk of NPC, EBV-related immunotherapy may lead to a breakthrough in advanced NPCs.

Results: In this review, we summarized the clinical characters of NPC, and several past and ongoing clinical trials of checkpoint inhibitors and EBV-CTLs (CTLs: cytotoxic T lymphocytes) in R/M NPC immunotherapy.

Conclusion: We conclude that although the evaluated effects of new immunotherapy drugs have brought us hope on NPC treatment, further phase II-III trials with larger samples are still required to improve the proportion and scheme of drug collocation for better clinical outcomes and less drug-related safety.

Keywords: CTLA-4; EBV; Immunotherapy; PD-1; R/M NPC.

PubMed Disclaimer

Cited by

Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
Lian D, Gan Y, Xiao D, Xuan D, Chen Y, Yang Y. Lian D, et al. Cancer Med. 2024 May;13(10):e7243. doi: 10.1002/cam4.7243. Cancer Med. 2024. PMID: 38752448 Free PMC article.
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, Zhang L, Tang H, Xiao T, Yang H, Gu W, Wang H, Chen P. Liu H, et al. Mol Cancer. 2024 Jan 22;23(1):20. doi: 10.1186/s12943-023-01928-2. Mol Cancer. 2024. PMID: 38254110 Free PMC article. Review.
Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
Hu YJ, Lu TZ, Zhang H, Fang M, Chen BJ, Guo QJ, Lin SJ, Feng P, Wang Y, Jiang TC, Gong XC, Pan JJ, Li JG, Xia YF. Hu YJ, et al. ESMO Open. 2023 Oct;8(5):101629. doi: 10.1016/j.esmoop.2023.101629. Epub 2023 Sep 1. ESMO Open. 2023. PMID: 37660406 Free PMC article.
Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma.
Secondino S, Pedrazzoli P, Basso S, Bossi P, Bianco A, Imarisio I, Pagani A, De Cicco M, Muscianisi S, Casanova M, Morosi C, Bergamini C, Benazzo M, Cossu Rocca M, Perotti C, Baldanti F, Zecca M, Licitra LF, Comoli P. Secondino S, et al. Front Immunol. 2023 Jul 11;14:1208475. doi: 10.3389/fimmu.2023.1208475. eCollection 2023. Front Immunol. 2023. PMID: 37497213 Free PMC article.
Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma.
Zhao LM, Shi AD, Yang Y, Liu ZL, Hu XQ, Shu LZ, Tang YC, Zhang ZL. Zhao LM, et al. Front Oncol. 2023 Mar 29;13:1140103. doi: 10.3389/fonc.2023.1140103. eCollection 2023. Front Oncol. 2023. PMID: 37064120 Free PMC article. Review.

See all "Cited by" articles

References

1. Benasso M (2013) Induction chemotherapy for squamous cell head and neck cancer: a neverending story? Oral Oncol 49(8):747–752 - DOI - PubMed
1. Bommareddy PK, Shettigar M, Kaufman HL (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 18(8):498–513 - DOI - PubMed
1. Chan JYW, Wei WI (2018) Three-dimensional endoscopy for endoscopic salvage nasopharyngectomy: preliminary report of experience. Laryngoscope 128(6):1386–1391 - DOI - PubMed
1. Chen BJ et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19(13):3462–3473 - DOI - PubMed - PMC
1. Chen YP et al (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64–80 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Benasso M (2013) Induction chemotherapy for squamous cell head and neck cancer: a neverending story? Oral Oncol 49(8):747–752 - DOI - PubMed

[2] Benasso M (2013) Induction chemotherapy for squamous cell head and neck cancer: a neverending story? Oral Oncol 49(8):747–752 - DOI - PubMed

[3] Bommareddy PK, Shettigar M, Kaufman HL (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 18(8):498–513 - DOI - PubMed

[4] Bommareddy PK, Shettigar M, Kaufman HL (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 18(8):498–513 - DOI - PubMed

[5] Chan JYW, Wei WI (2018) Three-dimensional endoscopy for endoscopic salvage nasopharyngectomy: preliminary report of experience. Laryngoscope 128(6):1386–1391 - DOI - PubMed

[6] Chan JYW, Wei WI (2018) Three-dimensional endoscopy for endoscopic salvage nasopharyngectomy: preliminary report of experience. Laryngoscope 128(6):1386–1391 - DOI - PubMed

[7] Chen BJ et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19(13):3462–3473 - DOI - PubMed - PMC

[8] Chen BJ et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19(13):3462–3473 - DOI - PubMed - PMC

[9] Chen YP et al (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64–80 - DOI - PubMed

[10] Chen YP et al (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64–80 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era

Affiliations

Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous